G.d. Searle & Company

Pharmacia Corporation

Tetra Discovery Partners, LLC

Northern Illinois University

Beryllium Discovery Corp.

Other

Decode Genetics Ehf

Northern Illinois Research Foundation

Emerald Biostructures, Incorporated

Timothy J Hagen

E Ann Hallinan

Barnett S Pitzele

Donald W Hansen, Jr

Mihaly V Toth

Sofya Tsymbalov

Arija A Bergmanis

Suzanne S Metz

Foe S Tjoeng

R Keith Webber

Mahima Trivedi

Karen B Peterson

Steven W Kramer

Kam F Fok

Mark E Gurney

Robert K Husa

Donna Lee Romero

Dale P Spangler

Robert Campbell

Joel R Walker

Lei Zhu

Xuesheng Mo

A Samuel Vellekoop

Rolando E Gapud

Michael John Clare

Ronald Keith Webber

Richard C Durley

Brian S Hickory

Alan E Moormann

Alok K Awasthi

Michelle A Promo

Jeffrey S Snyder

Scott S Ganser

Richard R Schartman

Len F Lee

Mark G Currie

Nizal S Chandrakumar

William M Moore

Jeffrey A Scholten

Pamela T Manning

Michael Mao

Foe Siong Tjoeng

Gunnar J Hanson

Michael L Vazquez

Richard M Weier

Robert E Manning

Michael A Stealey

He Huang

Xiangdong Xu

Joyce Zuowu Crich

Michael F Rafferty

Stephen C Houdek

Albert C Lee

Jean-Pierre Van Hoeck

Richard A Partis

David B Reitz

Michael B Tollefson

Francis J Koszyk

Patrick J Lennon

Bruce C Hamper

Robert Alan Chrusciel

Srinivasan Babu

Subo Liao

Jinglin J Li

James R Behling

Lifeng Geng

Shuyuan Liao

Sean T Nugent

Kevin A Babiak

Thomas Dale Owen

Donald E Korte

John R Medich

Daniel R Pilipauskas

Payman N Farid

Scott B Mohler

Dominique Bonafoux

Donna M Iula

Theresa R Fletcher

Serge G Wolfson

Maria Nguyen

David S Oburn

Brian E Hartnett

Angela M Scates

James A Sikorski

Lijuan Jane Wang

Margaret Lanahan Grapperhaus

Vincent Premaratna Sandanayaka

Mark A Massa

Jasbir Singh

Tao Xu

Gary E Schiltz

Shashidhar N Rao

Georgeta Hategan

Alexander Kiselyov

Kathleen T McLaughlin

Elizabeth R Gaillard

Robert F Campbell

James P Dillon

Alex Burgin

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

Heteroaryl inhibitors of PDE4

Compounds of formula I and II are described. In formulae I and II, X is &#x2014;NH&#x2014; or &#x2014;S&#x2014; and Y is &#x2014;CH&#x2550; or &#x2014;N&#x2550;. In formula I, Z is C-Calkylene, C-Calkenylene, C-Carylene, or C-Ccycloalkylene, or Z is absent. In formula I, R is hydrogen, halogen, &#x2014;OH, &#x2014;NO, C-Calkyl, C-Calkenyl, C-Caryl, &#x2014;O(C-Calkyl), or &#x2014;O(C-Caryl), wherein each hydrogen atom in C-Calkyl, C-Calkenyl, C-Caryl, &#x2014;O(C-Calkyl), and &#x2014;O(C-Caryl) is independently optionally substituted by halogen, &#x2014;OH, or &#x2014;NO. In formula II, R, R, R, and Rare each independently hydrogen, halogen, &#x2014;OH, &#x2014;NO, C-Calkyl, C-Calkenyl, or C-Caryl, wherein each hydrogen atom in C-Calkyl, C-Calkenyl, and C-Caryl is independently optionally substituted by halogen, &#x2014;OH, or &#x2014;NO. Methods of inhibiting bacteria are also described.

Oxadiazole and phenol derivatives as antibacterial and/or herbicidal agents

Pyrazolopyrimidine compounds for inhibition of isoprenoid biosynthesis have a formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), Rincludes an alkyl group and Rincludes an optionally substituted moiety selected from the group consisting of an optionally substituted benzyl group, an optionally substituted phenethyl group, an optionally substituted ethanol group, an optionally substituted ethyl acetate group, an optionally substituted methyl furan group, an optionally substituted 3-ethyl indole group, and a lower alkyl group. Compositions containing pyrazolopyrimidine compounds and methods for using pyrazolopyrimidine compounds are described.

Pyrazolopyrimidine antibacterial agents

A system is disclosed for simple, non-invasive, sustained delivery of ophthalmic substances to the interior of the eye, for the prevention and treatment of eye diseases and conditions. Liposomes and inverted micelles are disclosed as suitable vehicles, and timed release of the substances is effected. Delivery methods include coating of a lens or injection into the eye.

Timed release of substances to treat ocular disorders

Antibacterial and antimalarial IspF inhibitor compounds and compositions are described. Methods include administering described compounds and compositions to treat bacterial or parasitic infections and to inhibit parasite or bacterial growth.

Synthesis of novel inhibitors of isoprenoid biosynthesis (ISPF)

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.

Antibacterial IspF inhibitor compounds and compositions are described. Methods include administering described compounds and compositions to treat bacterial or parasitic infections and to inhibit or parasite or bacterial growth.

Synthesis of novel inhibitors of isoprenoid biosynthesis

The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula I: A particular embodiment is 

Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders

The present invention relates to compounds of Formula I:wherein A is (CH)-Q-(CH), wherein each CHmay be independently substituted with one or more substitution selected from the group consisting of: hydroxy, halo, alkoxy, lower alkyl, amino, aminoalkyl, alkylamino, alkenyl, and alkynyl; B is a 5 or 6 membered heteroaryl, or aryl, optionally saturated, or optionally substituted with R, R, or R; X is selected from the group consisting of: N and C; and Y and Z are independently selected from the group consisting of: N, C, CH, CR, S, and O; compositions comprising such compounds, intermediates thereof, methods of making such compounds, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.

Substituted pyrazolyl compounds for the treatment of inflammation

Growing community of inventors

Lisle, IL, United States of America

Timothy J Hagen